ADDvise Group AB has previously convened an extraordinary general meeting on 29 August 2024 to elect a new board member. Major shareholders in the company, who together represent approximately 30 percent of the shares in the company, have proposed that a new board member shall be elected to the board of directors to replace Staffan Torstensson, who will take over as CEO of ADDvise Group AB on 1 September 2024. Following discussions between the proposers and Kenneth Lindqvist, who as soon as an FDI notification is approved will become the largest shareholder in the company, the proposal in the notice has been withdrawn. Accordingly, the board of directors has resolved to cancel the extraordinary general meeting on 29 August 2024. Further, the board of directors has resolved to appoint Fredrik Celsing as the new chairman of the board of directors of ADDvise Group as of 1 September in connection with Staffan Torstensson taking over as CEO of the company. Staffan Torstensson will remain chairman of the board of directors until then and as a board member for the period thereafter until the next annual general meeting.
Presentations of ADDvise Group's board of directors and management can be found on ADDvise Group's website, www.addvisegroup.se.
For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se
About ADDvise
ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the company's Certified Adviser. More information is available at www.addvisegroup.com.